KRAS and neoplasm: In 14/15 (93.33%) patients with later on determined tumor tissue KRAS mutational status, the SNV detected by ddPCR in plasma (cfKRASmut) at any time point matched the KRAS SNV detected in tissue analysis (Supplemental Table 4), confirming the validity of ddPCR cfKRASmut analysis.